Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 10Lung Neoplasms 3Neuroblastoma 2Recurrence 1Non-Small Cell Lung Cancer ALK-positive 1Non Small Cell Lung Cancer Metastatic 1Neoplasm Metastasis 1Meningeal Carcinomatosis 1Glioma 1Glioblastoma 1Ganglioneuroblastoma 1Diffuse Intrinsic Pontine Glioma 1Carcinoma 1Brain Neoplasms 1Astrocytoma 1Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer 1Advanced Non-Small Cell Lung Cancer 1ALK Positive Non-small Cell Lung Cancer 1

Interventions

Magnetic Resonance Spectroscopy 7Cyclophosphamide 7dinutuximab 6Topotecan 5Isotretinoin 5Doxorubicin 5Biopsy 5sargramostim 4Vincristine 4Stem Cell Transplantation 4Specimen Handling 4Radiation 4Platinum 4Melphalan 4Colony-Stimulating Factors 4Cisplatin 4Carboplatin 41,2-diaminocyclohexaneplatinum II citrate 4Thiotepa 3Temozolomide 3Irinotecan 3Etoposide 3Congresses as Topic 33-Iodobenzylguanidine 3etoposide phosphate 2Razoxane 2Dexrazoxane 2Busulfan 2lorlatinib 1iberdomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ganglioneuroblastoma × lorlatinib × 1 year × Clear all
NCT03126916 2026-02-27

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Children's Oncology Group

Phase 3 Recruiting
750 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡